Evolent Health, Inc
EVH
Positions held
Your positionsEVH isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $447.71M | Enterprise value | $1.30B | Trailing P/E | — | Forward P/E | 9.81 |
| PEG | 1.93 | Price / book | 1.16 | Beta | 1.02 | Dividend yield | 0.00% |
| Revenue growth | 46.9% | Earnings growth | — | Gross margin | 17.2% | Operating margin | -1.3% |
| Profit margin | -24.1% | ROE | -67.0% | ROA | -0.8% | Debt / equity | 2.53 |
| Current ratio | 1.24 | Free cash flow | $184.30M | Analyst recommendation | buy | Mean target | $5.75 |
| 52w high | $8.33 | 52w low | $2.10 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $653M | $496M | $469M | $480M | $444M | — |
| Op margin | -1.5% | -2.1% | -4.4% | -0.3% | 0.5% | — |
| Net income | -$28.4M | -$26.6M | -$429M | -$20.9M | -$19.9M | — |
| Gross margin | 12.4% | 16.9% | 20.7% | 20.8% | 22.6% | — |
| Gross profit | $80.8M | $83.8M | $97.3M | $99.8M | $100M | — |
| Operating income | -$9.6M | -$10.6M | -$20.4M | -$1.4M | $2.0M | — |
- Revenue +31% vs prior quarter ($653M vs $496M).
- Gross margin 12.4% (was 16.9% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.9B | $2.6B | $2.0B | $1.4B | — |
| Op margin | -1.1% | -0.6% | -1.1% | -1.5% | — |
| Net income | -$535M | -$61.6M | -$113M | -$19.2M | — |
| Gross margin | 21.3% | 14.4% | 23.4% | 23.4% | — |
| Gross profit | $400M | $367M | $460M | $317M | — |
| Operating income | -$19.8M | -$14.1M | -$21.1M | -$19.9M | — |
Headlines — positive tone
• [OK · fundamentals] Evolent Health Shares Rise After Citigroup Upgrade
News
2026-09-21 · 3 Reasons to Avoid EVH and 1 Stock to Buy Instead
2026-09-21 · TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
2026-09-21 · TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
2026-09-16 · Q2 Healthcare Technology for Providers Earnings: Evolent Health (NYSE:EVH) Impresses
2026-09-12 · 1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Find Risky
2026-09-01 · 1 Value Stock with Promising Prospects and 2 That Underwhelm
2026-08-16 · 1 Healthcare Stock Worth Your Attention and 2 We Brush Off
2026-08-15 · 5 Must-Read Analyst Questions From Evolent Health’s Q2 Earnings Call
2026-08-13 · Evolent Health (EVH) Q2 2026 Earnings Call Transcript
2026-08-12 · Truist Securities Adjusts Price Target on Evolent Health to $6 From $7, Keeps Hold Rating
2026-08-12 · 3 Stocks Under $10 with Questionable Fundamentals
2026-08-11 · Evolent Health Shares Rise After Citigroup Upgrade
Price (daily)
Full chart · RSI · MACD · patterns